Display options
Cite
Quek RG, Fox KM, Wang L, et al. Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ Open Diabetes Res Care. 2015;3(1):e000132doi: 10.1136/bmjdrc-2015-000132.
Quek, R. G., Fox, K. M., Wang, L., Li, L., Gandra, S. R., & Wong, N. D. (2015). Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ open diabetes research & care, 3(1), e000132. https://doi.org/10.1136/bmjdrc-2015-000132
Quek, Ruben G W, et al. "Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk." BMJ open diabetes research & care vol. 3,1 (2015): e000132. doi: https://doi.org/10.1136/bmjdrc-2015-000132
Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND. Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ Open Diabetes Res Care. 2015 Sep 23;3(1):e000132. doi: 10.1136/bmjdrc-2015-000132. eCollection 2015. PMID: 26435839; PMCID: PMC4586941.
Copy Download .nbib Format: NLM
Share it on

BMJ Open Diabetes Res Care. 2015 Sep 23;3(1):e000132. doi: 10.1136/bmjdrc-2015-000132. eCollection 2015.

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk.

BMJ open diabetes research & care

Ruben G W Quek, Kathleen M Fox, Li Wang, Lu Li, Shravanthi R Gandra, Nathan D Wong

Affiliations

  1. Amgen Inc. , Thousand Oaks, California , USA.
  2. Strategic Healthcare Solutions, LLC , Aiken, South Carolina , USA.
  3. STATinMED Research , Plano, Texas , USA.
  4. University of California , Irvine, California , USA.

PMID: 26435839 PMCID: PMC4586941 DOI: 10.1136/bmjdrc-2015-000132

Abstract

OBJECTIVE: To examine real-world treatment patterns of lipid-lowering treatment and their possible associated intolerance and/or ineffectiveness among patients with type 2 diabetes mellitus initiating statins and/or ezetimibe.

RESEARCH DESIGN AND METHODS: Adult (aged ≥18 years) patients diagnosed with type 2 diabetes who initiated statins and/or ezetimibe from January 1, 2007 to June 30, 2011 were retrospectively identified from the IMS LifeLink Pharmetrics Plus commercial claims database. Patients were further classified into 3 high-risk cohorts: (1) history of cardiovascular event (CVE); (2) two risk factors (age and hypertension); (3) aged ≥40 years. Patients had continuous health plan enrolment ≥1 year preindex and postindex date (statin and/or ezetimibe initiation date). Primary outcomes were index statin intensity, treatment modification(s), possible associated statin/non-statin intolerance and/or ineffectiveness issues (based on treatment modification type), and time-to-treatment modification(s). Analyses for each cohort were stratified by age groups (<65 and ≥65 years).

RESULTS: A total of 9823 (history of CVE), 62 049 (2 risk factors), and 128 691 (aged ≥40 years) patients were included. Among patients aged <65 years, 81.4% and 51.8% of those with history of CVE, 75.6% and 44.4% of those with 2 risk factors, and 77.9% and 47.1% of those aged ≥40 years had ≥1 and 2 treatment modification(s), respectively. Among all patients, 23.2-28.4% had possible statin intolerance and/or ineffectiveness issues after accounting for second treatment modification (if any).

CONCLUSIONS: Among patients with type 2 diabetes with high cardiovascular disease risk, index statin treatment modifications that potentially imply possible statin intolerance and/or ineffectiveness were frequent.

Keywords: Cardiovascular Outcomes; Cardiovascular Risk Factors; Lipid-Lowering Drugs/Medication

References

  1. Clin Ther. 2012 Jan;34(1):190-9 - PubMed
  2. Vasc Health Risk Manag. 2008;4(3):525-33 - PubMed
  3. Diabetes Care. 2003 Jun;26(6):1796-801 - PubMed
  4. PLoS One. 2014 Nov 05;9(11):e111247 - PubMed
  5. Eur Heart J. 2011 Jul;32(14):1769-818 - PubMed
  6. Curr Med Res Opin. 2009 May;25(5):1247-60 - PubMed
  7. Curr Med Res Opin. 2014 Dec;30(12):2443-51 - PubMed
  8. J Clin Lipidol. 2015 Mar-Apr;9(2):129-69 - PubMed
  9. J Clin Lipidol. 2013 Sep-Oct;7(5):399-407 - PubMed
  10. Am J Med. 2012 Feb;125(2):176-82 - PubMed
  11. Cardiovasc Diabetol. 2009 May 18;8:26 - PubMed
  12. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14 - PubMed
  13. Lancet. 2010 Nov 13;376(9753):1670-81 - PubMed
  14. Clin Ther. 2006 Jan;28(1):26-35 - PubMed
  15. J Clin Lipidol. 2014 Nov-Dec;8(6 Suppl):S1-36 - PubMed
  16. Curr Med Res Opin. 2009 Feb;25(2):431-47 - PubMed
  17. Clin Ther. 2008 Nov;30(11):2167-79 - PubMed
  18. Circulation. 2013 Jan 1;127(1):96-103 - PubMed
  19. Lancet. 2008 Jan 12;371(9607):117-25 - PubMed
  20. J Clin Lipidol. 2012 May-Jun;6(3):208-15 - PubMed
  21. Diabetes Care. 2015 Jan;38 Suppl:S49-57 - PubMed
  22. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45 - PubMed
  23. Can J Cardiol. 2011 Sep-Oct;27(5):635-62 - PubMed
  24. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81 - PubMed
  25. Ann Intern Med. 2013 Apr 2;158(7):526-34 - PubMed
  26. Endocr Pract. 2015 Apr;21(4):438-47 - PubMed
  27. Am J Cardiol. 2014 May 15;113(10):1765-71 - PubMed
  28. Lancet. 2012 Aug 11;380(9841):581-90 - PubMed
  29. J Clin Lipidol. 2015 May-Jun;9(3):357-9 - PubMed
  30. J Clin Epidemiol. 1992 Jun;45(6):613-9 - PubMed
  31. MMWR Suppl. 2014 Oct 31;63(4):3-27 - PubMed
  32. Clin Ther. 2005 Oct;27(10):1639-46 - PubMed
  33. Am J Manag Care. 2007 Dec;13 Suppl 10:S276-81 - PubMed
  34. Endocr Pract. 2015 Apr;21 Suppl 1:1-87 - PubMed
  35. Eur Heart J. 2015 May 1;36(17 ):1012-22 - PubMed

Publication Types